Comparative Effectiveness of Roflumilast and Azithromycin for the Treatment of Chronic Obstructive Pulmonary Disease
Authors:
- 1 January 2021
- journal article
- research article
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 8 (4) , 450-463
Abstract
In chronic obstructive pulmonary disease (COPD) patients with exacerbations despite optimized bronchodilator therapy, roflumilast and chronic azithromycin are recommended options. Roflumilast is recommended in severe COPD patients with chronic bronchitis, whereas chronic azithromycin is more broadly indicated. The comparative effectiveness between these 2 treatments to reduce exacerbation rate remains unclear. Our objective was analysis of the Veterans Health Administration (VHA) database (medication and claims data without lung function or presence of chronic bronchitis or tobacco use) to compare the effectiveness of roflumilast and azithromycin on hospitalizations and mortality. The primary outcome of the study was cumulative incidences of first COPD-related and all-cause hospitalization. Sensitivity analysis on hospitalizations was conducted for VHA patients who also had Medicare. In 1302 roflumilast and 2573 azithromycin patients, the all-cause mortality rates at 1 year were 19% and 15%, respectively. The median times-to-all-cause death were 47 months (interquartile range [IQR] 16-81) for the roflumilast and 48 months (IQR 20-83) for the azithromycin groups. Roflumilast was associated with higher mortality (hazard ratio [HR] 1.16; 95% confidence interval [CI], 1.04-1.29). Roflumilast showed no significant association for COPD-related hospitalization (subdistribution HR [SHR]=1.14, 95% CI, 1.00-1.29) and all-cause hospitalization (HR 1.07, 95% CI, 0.97-1.18). For patients with Medicare (N=2030), roflumilast was associated with higher COPD-related (SHR 1.21; 95% CI, 1.05-1.41) and all-cause (SHR 1.23; 95% CI, 1.09-1.38) hospitalizations. Roflumilast was associated with higher hazard ratios for death, COPD-related hospitalizations, and all-cause hospitalizations in COPD patients only after adjustment for VHA and external Medicare events. Prospective clinical trials are needed to directly compare the relative efficacy of these therapies.Keywords
This publication has 21 references indexed in Scilit:
- The clinical and economic burden of chronic obstructive pulmonary disease in the USAClinicoEconomics and Outcomes Research, 2013
- Azithromycin for Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancerBMC Medical Research Methodology, 2010
- Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsThe Lancet, 2009
- Long-term Erythromycin Therapy Is Associated with Decreased Chronic Obstructive Pulmonary Disease ExacerbationsAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up studyThorax, 2004
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002
- Are Patients at Veterans Affairs Medical Centers Sicker?Archives of internal medicine (1960), 2000
- Time Course and Recovery of Exacerbations in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Effect of Exacerbation on Quality of Life in Patients with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998